Y-mabs announces publication in cancers

Naxitamab-based chemo-immunotherapy significantly improves long-term outcomes when administered early during the course of treatment naxitamab-based chemo-immunotherapy significantly improves long-term outcomes when administered early during the course of treatment
YMAB Ratings Summary
YMAB Quant Ranking